foxo4-dri human trials results The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4-DRI induces keloid senescent fibroblast
Description
2020 Dec 11;11:601325
Study selection Study inclusion criteria were as follows: patients diagnosed with IC/BPS, interventions included relevant treatments, comparisons were specified as control or placebo, outcomes were mean differences for individual symptoms (pain, frequency, urgency and nocturia) and structured questionnaires (ICPI, ICSI, PUF and FBV) using an RCT study design
Extended room temperature storage (hours or days) accelerates degradation
61 Clinical trials in humans have evaluated the benefits of B12 in a number of painful conditions
